Episode 146: Overviewing Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer Care

Link to episode: https://www.neurologylive.com/episode... In this episode, "Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer’s Care" John Sims, MD, head of medical development for donanemab at Eli Lilly and Company, joins NeurologyLive to discuss the recently updated label for donanemab (Kisulna), an anti-amyloid Alzheimer disease (AD) therapy. Sims breaks down the key safety data from the TRAILBLAZER-ALZ-6 study (NCT05738486) that led to a newly approved titration-based dosing regimen aimed at minimizing ARIA risk. He outlines considerations for clinicians treating patients with early-stage AD, including genotype-based stratification, ARIA severity patterns, and implications for prescribing and patient counseling. Furthermore, Sims also shares takeaways about donanemab’s clinical impact and how the results may shape the future of anti-amyloid therapy development and AD care. Episode Breakdown: 1:00 – Overview of the new donanemab dosing regimen and its goal to reduce ARIA risk 2:30 – Rationale behind the four different dosing strategies tested in Trailblazer-ALZ-6 6:00 – What clinicians should know about patient risk and genotype testing 8:00 – Neurology News Minute 10:10 – Clinical implications of the updated label, including risk-benefit conversations 13:45 – Surprising results from the trial, particularly for APOE4 homozygous patients